Expression and lytic efficacy assessment of the<i>Staphylococcus aureus</i>phage SA4 lysin gene

Mishra, Anil Kumar; Rawat, Mayank; Nagaleekar, Viswas Konasagara; Abhishek, Abhishek; Kumar, Sujeet; Reddy, Mallamma V.

doi:10.4142/jvs.2013.14.1.37

Cited by 13 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the application of lytic phage in single dose proved to be innovative and effective therapy for treatment of septic chronic wounds. Our findings related with bacteriophage therapy showed agreement with the findings of other workers like Slopek et al (1987); Alisky et al (1998);Mathur et al (2003);W ills et al (2005); Mishra et al (2012) and Breyne et al (2017) they reported the success in bacteriophage therapy was 60-100% against suppurative infections and abscesses. Bacteriophage may be inducing IFN gamma and some other interferon's which leads to good healing process.…”

Section: Resultssupporting

confidence: 92%

“…Phages lysates have been extensively used to prevent and treat many numbers of chronic septic bacterial infections with great recovery rate (Heo et al, 2009;Mishra et al, 2012 andBreyne et al, 2017). Present study was conducted to isolate, characterized and assess the antimicrobial activity of phage lysate in chronic septic wounds.…”

Section: Bacteriophages: a Potential New Therapeutic Alternate To Antmentioning

confidence: 99%

See 1 more Smart Citation

Bacteriophages: A Potential New Therapeutic Alternate to Antibiotics to Treat Chronic Septic Wounds in Large Animals

Shukla¹,

Nayak²,

Sharma³

et al. 2021

IJAR

View full text Add to dashboard Cite

Background: Overuse of antibiotics is a major problem in the treatment of chronic infections. The antibiotic treatment is frequently non-curative due to emergence of antibiotic resistance, thus alternative treatment is necessary. The natural ability of pathogens to develop resistance is not only a threat to animal health but also leads to accumulation of antibiotic resistance determinants or resistant bacteria livestock products. Phage therapy has been developed as an alternative therapeutic approach against antibiotic resistance microorganisms.Methods: In present study 150 samples of sewage were collected from livestock farm, NDVSU, Jabalpur (M.P.). Bacteriophages were isolated and characterized from the collected sewage samples. “Cocktail” of the recovered phage lysate isolates (ØVS1, ØVS5, ØVS9 and ØVS27) was prepared for assessment of therapeutic utility of S. aureus phages in chronic septic infections. Therapeutic trial was performed in large animals (cattle and buffalo) at livestock farm, Adhartal, NDVSU, Jabalpur (MP.). Pathogens isolated from chronic septic wounds were showing antibiotic resistance but the bacteria were sensitive to phage lysate. Phage ‘cocktail’ was applied topically over the chronic septic wounds as single dose. Follow up of the cases was done at regular intervals (0, 5 and 10 days) which included clinical examination of wound by appearance, status of discharge and formation of granulation tissue.Result: Six animals showed complete recovery (60%) out of 10 animals from wounds as predicted by progressive healing status of wounds till the formation of granulation tissue within 10 days after phage application. Thus, recovery was much higher than the conventional antibiotic therapy normally used for the treatment of chronic septic wound infections in animals.

show abstract

Section: Resultssupporting

confidence: 92%

Section: Bacteriophages: a Potential New Therapeutic Alternate To Antmentioning

confidence: 99%

Bacteriophages: A Potential New Therapeutic Alternate to Antibiotics to Treat Chronic Septic Wounds in Large Animals

Shukla¹,

Nayak²,

Sharma³

et al. 2021

IJAR

View full text Add to dashboard Cite

show abstract

“…Numerous effective lysins derived from various species (Streptococcus pneumoniae, S. pyogenes, S. agalactiae, Staphylococcus, etc.) have been reported in recent years (30,31,(38)(39)(40). However, only three S. suis phage lysins (PlySs1, PlySs2, and LySMP) have been reported (24,26,27).…”

Section: Discussionmentioning

confidence: 99%

Prophage Lysin Ply30 Protects Mice from Streptococcus suis and Streptococcus equi subsp. zooepidemicus Infections

Tang

Wang

et al. 2015

Appl Environ Microbiol

View full text Add to dashboard Cite

Streptococcus suis and Streptococcus equi subsp. zooepidemicus are capable of infecting humans and various animals, causing significant problems for the worldwide swine industry. As antibiotic resistance has increased, lysosomal enzymes encoded by phages have shown potential for use against pathogenic bacteria. In this study, a novel bacteriophage lysin, Ply30, encoded by the S. suis prophage phi30c, was recombinantly expressed and purified. Ply30 showed high bacteriolysis activity on S. suis and S. equi subsp. zooepidemicus in vitro. The ratio of the optical density at 600 nm (OD 600 ) with treatment versus the OD 600 with no treatment for most tested S. suis and S. equi subsp. zooepidemicus strains decreased from 1 to <0.3 and <0.5, respectively, within 1 h. The results of plate viability assays showed that treated bacteria suffered a 1-to 2-log decrease in CFU within 1 h. The optimal concentration of Ply30 was 50 g/ml, and the optimal pH was 7. Moreover, Ply30 maintained high activity over a wide pH range (pH 6 to 10). The MICs of Ply30 against Streptococcus strains ranged from 16 to 512 g/ml. In vivo, a 2-mg dose of Ply30 protected 90% (9/10 mice) of mice from infection with S. equi subsp. zooepidemicus and 80% (8/10 mice) of mice from infection with S. suis. Seven days after lysin Ply30 treatment, bacterial loads were significantly decreased in all tested organs and blood compared with those at 1 h postinfection without Ply30 treatment. Ply30 showed in vitro and in vivo antimicrobial efficiency and protected mice against two kinds of bacterial infections, indicating that Ply30 may be an effective therapeutic against streptococci. Streptococcus suis and Streptococcus equi subsp. zooepidemicus are emerging zoonotic, pathogenic, Gram-positive bacteria capable of infecting humans and various animals, such as horses, pigs, ruminants, guinea pigs, monkeys, cats, and dogs (1-3). S. suis can cause septicemia, arthritis, and meningitis in pigs (4). Liu et al. identified 33 serotypes (serotypes 1 to 31, 33, and 1/2) of S. suis according to the variation of capsular antigens (5, 6). Two outbreaks of S. suis have occurred in China. One was in Sichuan Province in July 2005, with 215 humans infected. The other was in Jiangsu Province, in 1998, and 25 humans were involved, 14 of whom died (7-9). By the end of 2012, 1,584 cases had been reported in the literature, most of which were associated with pigs and human infections (10). Besides S. suis, S. equi subsp. zooepidemicus is another important pathogen that can cause upper respiratory tract disease in pigs and rheumatic fever and glomerulonephritis in humans (11, 12). S. equi subsp. zooepidemicus shares Ͼ80% DNA sequence similarity and important virulence factors with Streptococcus pyogenes (13). The sequelae of S. pyogenes infections and the symptoms caused by S. equi subsp. zooepidemicus are also similar (12). In recent years, several outbreaks of S. equi subsp. zooepidemicus infections have been reported in different countries (11,14,15).The main and conventional prev...

show abstract

“…They parasitize only host cells that are susceptible to infection, so they can be used as ideal antibacterial biological agents to replace antibiotics [8]. With the use of antibiotics, the problem of resistant bacteria is becoming increasingly serious; therefore, there is an urgent need for phage-derived products (endolysins) and phages to replace antibiotic drugs [9,10]. A number of phages PVS-1, PVS-2, PVS-3 and vB_VspP_pVa5, that infect V. splendidus have been reported, and their possess the efficacy to inactivate V. splendidus, the cultures infected with PVS-1, PVS-2, PVS-3 and vB_VspP_pVa5 at a MOI of 10 started to show significant decreases in optical density (OD 600 ) compared with the control culture at 3 h after infection (P < 0.05) [11].…”

Section: Introductionmentioning

confidence: 99%

Isolation, characterization and application of a lytic phage vB_VspM_VS1 against Vibrio splendidus biofilm

Duan,

Jiang,

Guo

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Vibrio splendidus is a common pathogen in the ocean that infects Apostichopus japonicus, Atlantic salmon and Crassostrea gigas, leading to a variety of diseases. In this study, a virulent phage vB_VspM_VS1, which infects V. splendidus, was isolated from aquaculture ponds in Dalian, China, and it belongs to the family Straboviridae in the order Caudoviricetes. vB_VspM_VS1 had an adsorption rate of 96% in 15 min, a latent period of 65 min, and a burst size of 140 ± 6 PFU/cell. The complete genome of phage vB_VspM_VS1 consists of a linear double-stranded DNA that is 248,270 bp in length with an average G + C content of 42.5% and 389 putative protein-coding genes; 116 genes have known functions. There are 4 tail fiber genes in the positive and negative strands of the phage vB_VspM_VS1 genome. The protein domain of the phage vB_VspM_VS1 tail fibers was obtained from the Protein Data Bank and the SMART (http://smart.embl.de) database. Bacterial challenge tests revealed that the growth of V. splendidus HS0 was apparently inhibited (OD600 < 0.01) in 12 h at an MOI of 10. In against biofilms, we also showed that the OD570 value of the vB_VspM_VS1-treated group (MOI = 1) decreased significantly to 0.04 ± 0.01 compared with that of the control group (0.48 ± 0.08) at 24 h. This study characterizes the genome of the phage vB_VspM_VS1 that infects the pathogenic bacterium V. splendidus of A. japonicus.

show abstract

Expression and lytic efficacy assessment of theStaphylococcus aureusphage SA4 lysin gene

Cited by 13 publications

References 32 publications

Bacteriophages: A Potential New Therapeutic Alternate to Antibiotics to Treat Chronic Septic Wounds in Large Animals

Bacteriophages: A Potential New Therapeutic Alternate to Antibiotics to Treat Chronic Septic Wounds in Large Animals

Prophage Lysin Ply30 Protects Mice from Streptococcus suis and Streptococcus equi subsp. zooepidemicus Infections

Isolation, characterization and application of a lytic phage vB_VspM_VS1 against Vibrio splendidus biofilm

Contact Info

Product

Resources

About